SIV antigen-specific effects on immune responses induced by vaccination with DNA electroporation and plasmid IL-12  by Lindsay, Ross W. et al.
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Molecular  adjuvants  are important  for augmenting  or  modulating  immune  responses  induced by  DNA
vaccination.  Promising  results  have  been  obtained  using  IL-12  expression  plasmids  in  a  variety  of  disease
models  including  the SIV  model  of  HIV infection.  We  used  a mouse  model  to evaluate  plasmid  IL-12 (pIL-
12)  in  a  DNA  prime,  recombinant  adenovirus  serotype  5  (rAd5)  boost  regimen  speciﬁcally  to  evaluate  the
effect  of IL-12  expression  on  cellular  and  humoral  immunity  induced  against  both  SIVmac239  Gag  and
Env  antigens.  Priming  with  electroporated  (EP)  DNA  +  pIL-12  resulted  in a 2–4-fold  enhanced  frequency
of  Gag-speciﬁc  CD4  T cells  which  was  maintained  through  the  end  of  the  study  irrespective  of  the pIL-12
dose,  while  memory  Env-speciﬁc  CD4  + T cells  were  maintained  only  at the low dose of  pIL-12. There  was
little  positive  effect  of pIL-12  on the  humoral  response  to  Env,  and  in fact, high  dose  pIL-12  dramatically cell
ntibody
reduced  SIV  Env-speciﬁc  IgG.  Additionally,  both  doses  of  pIL-12  diminished  the  frequency  of  CD8  T-
cells  after  DNA  prime,  although  a  rAd5 boost  recovered  CD8  responses  regardless  of  the  pIL-12  dose.  In
this  prime-boost  regimen,  we  have  shown  that  a high  dose  pIL-12  can  systemically  reduce  Env-speciﬁc
humoral  responses  and  CD4T  cell frequency,  but  not  Gag-speciﬁc  CD4+  T cells.  These  data  indicate  that
it  is important  to independently  characterize  individual  SIV  or HIV  antigen  immunogenicity  in multi-
antigenic  vaccines  as  a function  of  adjuvant  dose.
 201©
. Introduction
Despite improvements in the control of virus replication using
IV anti-retroviral therapies and additional efforts such as micro-
icide use and pre-exposure prophylaxis, an effective HIV vaccine
emains the most viable solution to control the HIV pandemic. DNA
accines are attractive due to their safety and ease of engineering
nd manufacturing [1]. First generation HIV based DNA vaccines
ailed to generate high levels of immunogenicity in humans [2],
ut subsequent progress on plasmid optimization, molecular adju-
ants and improved delivery systems have all contributed to the
ncreased efﬁcacy of DNA vaccines and renewed interested in their
     
∗ Corresponding author at: International AIDS Vaccine Initiative, AIDS Vaccine
esign  and Development Laboratory, 140 58th Street, Building A, Suite 8J, Brooklyn,
Y 11220, USA. Tel.: +1 646 381 8061.
E-mail address: rlindsay@iavi.org (R.W. Lindsay).
264-410X     ©   2013  The  Authors.  Published  by  Elsevier  Ltd.  
ttp://dx.doi.org/10.1016/j.vaccine.2013.08.011
Open access under CC BY-NC-SA3 The Authors. Published by Elsevier Ltd. 
application to HIV vaccine development [3–8]. In particular, the
use of electroporation (EP) has signiﬁcantly enhanced immune
responses in animal models [9–13].
Co-delivery of DNA encoding molecular adjuvants with DNA
encoding antigen is a strategy used to augment or modulate the
immune response. A variety of cytokines and chemokines have
been tested including GM-CSF, IL-2, IL-15, CCL25, CCL27 and IL-12
[14–18]. Co-delivery of plasmid IL-12 (pIL-12) enhances T cell
responses in non-human primates (NHPs) [10,19–21], which may
play a role in protection from SHIV challenge [20]. Additionally,
the combination of delivery of DNA by EP and the inclusion of
pIL-12 has been shown to enhance the potency of DNA vaccines in
NHPs [10,21]. As a result we tested EP delivery of SIV DNA + pIL-12
followed by a rAd5 boost in the NHP SIV challenge model and
observed an approximately 2 log reduction in peak viral load and
4 log reduction in set point viral load following infection [22].
Analysis of the immune response when pIL-12 was  included,
Open access under CC BY-NC-SA license.demonstrated an increase in frequency of CD4+ T cell responses,
which were characterized to be multifunctional and maintained
following a rAd5 boost [22]. As a result of these studies, an
analogous strategy is now being tested in phase I clinical trials
 license .
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ClinicalTrials.gov Identiﬁer: NCT01496989). The goals of this trial
re to determine the safety of the vaccine regimen and to assess
he effect of different levels of pIL-12 in the DNA prime.
As  a guide for ongoing analysis of both NHP and human studies
nvolving pIL-12, we evaluated the effect of pIL-12 on the immuno-
enicity of SIV Gag and Env DNA vaccines in the mouse model to
etermine the impact of murine pIL-12 on the humoral and cel-
ular immune responses to both antigens. Speciﬁcally, we  studied
he effect of high and low dose pIL-12 on the immune responses
nduced against two co-delivered SIV immunogens and observed a
ifferential impact on the maintenance of Gag versus Env-speciﬁc T
ells at a high dose of pIL-12. Additionally, we describe the require-
ent of EP and low dose pIL-12 to generate a balanced cellular and
umoral immune response to both antigens. These results suggest
hat pIL-12 dose optimization for each antigen individually, as well
s in combination, may  need to be conducted to achieve the desired
utcome in future multi-antigen pre-clinical and clinical studies.
.  Materials and methods
.1.  Animals
C57BL/6 mice were purchased from the Jackson Laboratory
nd maintained at SUNY Downstate Medical Center under spe-
iﬁc pathogen free conditions. The SUNY Downstate Institutional
nimal Care and Use Committee reviewed and approved all exper-
mental protocols.
.2.  Vectors
DNA and rAd5 vaccine immunogens used in this study
ere as previously described [22]. Brieﬂy, immunogens were
esigned from the SIVmac239 sequence (GenBank accession num-
er M33262). The Gag plasmid expressed myristoylated Gag
rotein and the Env plasmid expressed native gp160. Aldevron LLC
Fargo, ND) produced and puriﬁed large-scale plasmid DNA used for
accination. Both DNA and rAd5 share the same insert sequences,
hich were optimized for expression in mammalian cells. rAd5
ectors were constructed in a E1A, partial E1B and E3 genetic
ackground using AdEasy adenoviral vector system (Stratagene, La
olla, CA). The murine pIL-12 used in this study expressed the IL-12
35 and p40 subunits from separate promoters to generate the opti-
al  expression ratio of each subunit and generate maximal levels
f bioactive IL-12 p70 [23].
.3. Immunizations
Animals were anesthetized and the area over the tibialis anterior
haved before immunization with 30 g SIVmac239 Gag and Env
NA with or without pIL-12 (0.3 or 25 g). For electroporation, 4 s
fter DNA injection, two electrical pulses for 40 ms at 250 mA were
pplied to the injection site using the TriGridTM Delivery System
Ichor Medical Systems, Inc., San Diego, CA). Animals were primed
ith DNA twice, 4 weeks apart before an IM boost at week 8 with
 × 108 particles of rAd5 vectors encoding SIVmac239 Gag and Env.
ag antigens were immunized into the left leg while Env antigens
ere immunized into the right leg.
.4. Multiparameter ﬂow cytometry
At various times following immunization, 1.5 × 106 leukocytes
rom the spleen were incubated with 2 g/ml anti-CD28 (BD
iosciences), 10 g/ml brefeldin A (Sigma–Aldrich), and 15-mer
verlapping peptide pools or 2 g/ml each of the DD13 (DRFYK-
LRAEQTD, CD4 epitope) [24] or AL11 (AAVKNWMTQTL, CD8) [25]
IV Gag peptides for 5 h at 37 ◦C before intracellular cytokine31 (2013) 4749– 4758
staining. Control stimulations were prepared for each animal by
incubating leukocytes with only anti-CD28 and brefeldin A. For
all T cell data, the control co-stimulation response was subtracted
from the peptide-stimulated response. Cells were stained with
LIVE/DEAD Fixable Violet Dead Cell Stain (Molecular Probes), CD3,
CD4, IFN, IL-2, TNF (BD Biosciences), and CD8 (BioLegend). Cells
were resuspended in 0.5% paraformaldehyde before being acquired
on a modiﬁed BD LSR II ﬂow cytometer and analyzed using FlowJo
software version 9.4 (Tree Star) and SPICE version 5.22 [26].
2.5.  ELISA
Anti-SIV Env speciﬁc IgG in serum was  quantiﬁed by ELISA.
Brieﬂy, serial dilutions of heat-inactivated serum were incubated in
96 well plates coated with 100 ng/well of SIVmac239 gp140, SIV-
mac251 gp120 or SIVsmE660 gp140 (Immune Technology Corp.,
NY). Plates were blocked with 3% BSA before addition of serial
diluted serum samples and detection of IgG with anti-mouse IgG-
HRP (Jackson ImmunoResearch, PA).
2.6. Statistics
Statistical signiﬁcance of T cell cytokine production was calcu-
lated in SPICE software using the Wilcoxon Signed Rank Test, bars
represent the median response. Signiﬁcance of antibody produc-
tion was  calculated by two-tailed Mann–Whitney test using PRISM
software.
3. Results
3.1. The frequency and quality of Th1 CD4+ T cell responses are
enhanced  by electroporation of DNA vaccines and the inclusion of
low dose plasmid IL-12
To  determine the effect of using pIL-12 adjuvant and EP in the
vaccine regimen, mice were immunized twice by IM injection or
EP, 4 weeks apart with Gag plasmid DNA in the left leg and Env
plasmid DNA in the right leg in the presence or absence of low
dose pIL-12 (0.3 g). SIV-speciﬁc T cell responses were analyzed by
peptide stimulation and intracellular cytokine staining two  weeks
following the second DNA immunization (Fig. 1). Compared to
IM injection without molecular adjuvant, the Gag-speciﬁc CD4+
T cells stimulated with the peptide pool were enhanced 2–3-fold
in animals immunized by EP with or without low dose pIL-12 or
IM + pIL-12 (Fig. 1A). Comparing these data to cells stimulated with
only the dominant CD4 H-2b Gag epitope, DD13 (included in the
Gag pool), the effect of IL-12 was  evident and it was clear and the
CD4+ T cell response was dominated by responses directed toward
the DD13 peptide in the pIL-12 groups (Fig. 1A). Examining the Env-
speciﬁc CD4+ T cell response (Fig. 1B) showed that immunization
by IM with pIL-12 signiﬁcantly reduced the CD4+ T cell response in
Env peptide pool 1 and had little effect on pool 2 compared to IM
injection without pIL-12. EP had a modest effect on T cells stimu-
lated with pool 1 but no effect on pool 2. EP with pIL-12 enhanced
the frequency of responding CD4+ T cells in pool 2 only. An adju-
vant effect of pIL-12 on Env-speciﬁc CD4+ T cells was not observed
in the IM immunized animals as was seen with Gag.
CD8+ T cells speciﬁc for SIV Gag (Fig. 1C) and Env (Fig. 1D) were
mildly enhanced by EP delivery of DNA; however, animals immu-
nized by EP with pIL-12 showed a 2–5-fold reduction as compared
to those who  were vaccinated by EP only. Both the dominant CD8
H-2b Gag epitope, AL11, and the Gag peptide pool responses (not
including AL11) show the same trend of diminished CD8 T cell
frequency when pIL-12 was included in EP delivery of the DNA
(Fig. 1C).
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Fig. 1. Frequency of CD4+ (A and B) and CD8+ (C and D) SIV-speciﬁc cytokine secreting T cells following DNA immunization. Mice were immunized twice, 4 weeks apart
with SIV Gag and Env DNA (30 g) by IM or EP +/− pIL-12 (0.3 g). Splenocytes were harvested two weeks after the second immunization, incubated ex vivo for 5 h with Gag
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One measure of T cell immune response quality is the produc-
ion of any combination of IFN, IL-2 or TNF in response to speciﬁc
ntigen stimulation at the single cell level. Multifunctional T cells
re capable of producing all three cytokines and of producing more
f each cytokine on a per cell basis. The majority of the antigen
peciﬁc Th1 CD4+ T cells that deﬁne the quality of the response
an be subdivided into populations based on IFN secretion (sin-
le positive), IFN and TNF (double positive) and IFN, TNF and
L-2 (triple positive). When the quality of the Gag (Fig. 2A) and Env-
peciﬁc (Fig. 2B) CD4+ T cell responses were quantiﬁed, triple pos-
tive Gag-speciﬁc CD4+ T cells were lowest after IM immunization
nd increased by IM + IL12, EP, or EP + IL12, although the positive
ffect of EP and IL12 did not appear to be additive (Fig. 2A). A model
f Th1 differentiation proposes sequential loss of T cell functions,
amely IL-2 and TNF, upon multiple/prolonged antigen exposure
27,28], and we observed that pIL-12 might have enhanced differ-
ntiation of the Gag-speciﬁc CD4+ T cell response in this manner.
his was consistent with detection of an increased frequency of
ouble positive (IFN/TNF) CD4+ T cells that appeared to be pri-
arily in response to the dominant CD4 epitope DD13 (Fig. 2A).
The  frequency of multifunctional Env-speciﬁc CD4+ T cells
as predominantly enhanced in the animals receiving EP + pIL-12
nd these were directed toward epitopes in Env pool 2 (Fig. 2B).
n contrast to the Gag-speciﬁc effects, vaccination with EP ornv pooled peptides (B and D), anti-CD28 and brefeldin A before being analyzed by
reting T cells (%) producing IFN, IL-2 and TNF are shown and bars represent the
t from animals immunized by IM.
IM  + pIL-12 did not signiﬁcantly increase numbers of multifunc-
tional T cells, and instead, the maximum frequency of Env-speciﬁc
multifunctional cells required the combination of EP + pIL-12.
3.2. High dose plasmid IL-12 dampens DNA-primed CD4+ Th1
and  CD8+ T cell responses
In  earlier studies, high doses of pIL-12 (25–50 g) were required
to induce an adjuvant effect with HIV Env DNA  [16,29]. There-
fore, we tested EP SIV Env DNA with both a low (0.3 g) and high
dose (25 g) of pIL-12 in combination with a low dose pIL-12/Gag
DNA immunization delivered to a separate vaccination site. The
peak Gag responses induced by EP or EP plus a low dose of pIL-12
(Figs. 1 and 3) were abrogated using a higher dose of pIL-12 (Fig. 3A).
However, this inhibitory effect did not appear to prevent CD4+ T
cells from being boosted by a rAd5-Gag and rAd5-Env immuniza-
tion at week 8 as seen by the expansion of both Gag and Env-speciﬁc
CD4+ T cells at week 10. Additionally, as a result of the initial inhi-
bition, the EP + pIL-12 high Gag-speciﬁc CD4+ T cells expanded to a
greater extent that those in the low dose group with approximately
a 16-fold expansion from week 6 to week 10 compared to a 3-fold
expansion in the low dose group. The Env-speciﬁc response in pool
1 was enhanced by low dose pIL-12, and there was a trend for the
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Fig. 2. Quality of SIV Gag-speciﬁc (A) and SIV Env-speciﬁc (B) CD4+ Th1 cells secreting IFN, IL-2 and TNF in any combination after DNA immunization. Mice were immunized
twice, 4 weeks apart with SIV Gag and Env DNA (30 g) by IM or EP +/− pIL-12 (0.3 g). Splenocytes were harvested two weeks after the second immunization, incubated
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esponse to peptides in pool 2 to be enhanced by high dose pIL-12
Fig. 3B).
Gag-speciﬁc CD8+ T cell responses were inhibited by both low
nd high dose pIL-12 at week 6 compared to EP alone (Fig. 3C),
hile Env-speciﬁc CD8+ T cells were signiﬁcantly reduced by high
ose pIL-12 compared to low dose pIL-12 and EP alone (Fig. 3D). As
bserved with the CD4+ T cells, this inhibitory effect did not prevent
he expansion of the CD8+ T cells to both antigens following a boost
ith rAd5. CD8+ T cells in both low and high dose groups expanded
o a similar frequency as those in the EP only group.
The quality of the Gag-speciﬁc CD4+ T cell responses at week
0 revealed a trend toward increased multifunctional cells. Upon
nalysis of the dominant peptide response (DD13) within the pool,
 signiﬁcant increase in the frequency of multifunctional CD4+ T
ells was observed in both high and low dose pIL-12 dose groups as
ompared to EP alone (Fig. 3E). The quality of the Env-speciﬁc CD4+
 cell response (Fig. 3F) was  slightly different with low dose pIL-12
nhancing the multifunctional response to epitopes represented by
ool 1 while the high dose pIL-12 was inhibitory. For pool 2, there
as a trend toward both low and high dose pIL-12 enhancing a mul-
ifunctional response. The quality and frequency of multifunctional
D8+ T cells following the boost was similar among all groups with
 mixed population of multifunctional cells (data not shown).
.3.  The frequency and quality of memory Th1 CD4+ T cell
esponses is enhanced by inclusion of pIL-12 in an EP but not an
M  DNA prime
At  the end of the study (week 14), the frequency of Gag-speciﬁc
D4+ T cell responses were approximately 2–3-fold higher in ani-
als immunized with the combination of EP and low dose pIL-12
s compared to EP alone or IM +/− pIL-12 (Fig. 4A). This response
as comprised of approximately 50% DD13 speciﬁc responses and
0% responses to other epitopes in the Gag peptide pool. A modest
ncrease also was observed in the frequency of Env-speciﬁc CD4+
 cells with 2–3 animals in the EP + low dose pIL-12 group. Upon and Env pool 2 peptides (B), anti-CD28 and brefeldin A before being analyzed by
 T cells (%) producing IFN, IL-2 and TNF in any combination are shown with bars
niﬁcantly different from animals immunized by IM.
analysis  of the quality of the Th1 Gag-speciﬁc immune response,
a greater frequency of multifunctional memory CD4+ T cells were
maintained in the EP + pIL-12 group as compared to other vaccine
groups (Fig. 4B). Similar data was  observed with the Env-speciﬁc
CD4+ T cells (data not shown). The frequency of Gag-speciﬁc CD8+
T cells at week 14 were inhibited when pIL-12 was included in
the IM vaccination (Fig. 4C). This effect was  not however observed
in Env-speciﬁc responses with the memory response being pre-
dominantly represented by peptides in pool 1. The quality of the
CD8+ T cell response remained similar between all groups (data not
shown).
3.4. Multifunctional Gag and Env-speciﬁc memory T cell
responses differ in their ability to be maintained when the prime
includes  high dose pIL-12
While  the total frequency of Gag-speciﬁc CD4+ T cells induced
with EP immunization and low or high dose pIL-12 remained
enhanced at week 14 compared to EP immunization alone
(Figs. 4A and 5A), there was a trend for high dose pIL-12 to reduce
the frequency of Env-speciﬁc responses (Fig. 5A). The frequency of
Env-speciﬁc T cells in the high dose pIL-12 group was similar to EP
immunization without pIL-12. This became more apparent upon
analysis of the quality of the Gag-speciﬁc (Fig. 5B) and Env-speciﬁc
(Fig. 5C) immune responses. In both pIL-12 dose groups, the fre-
quency of multifunctional Gag-speciﬁc CD4+ T cells were enhanced
approximately 2-fold as compared to the EP immunization alone
(Fig. 5B). Env-speciﬁc (Fig. 5C) responses, however, only demon-
strated maintenance of multifunctional memory CD4+ T cells when
the prime included low dose pIL-12, irrespective of the fact that
these cells were boosted with Ad5 at week 10 (Fig. 3F).
The  frequency of Gag and Env-speciﬁc CD8+ T cells remained
similar at the end of the study. Env-speciﬁc responses did however
appear to be blunted in 2 out of 4 animals receiving the high dose
pIL-12 (Fig. 5D). The quality of the CD8+ T cell response remained
similar between all groups (data not shown).
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Fig. 3. Effect of pIL-12 on the frequency of SIV Gag and Env-speciﬁc cytokine secreting T cells following EP immunization. Mice were immunized by EP twice, four weeks
apart with Gag and Env plasmids and low dose (0.3 g) or high dose (25 g) pIL-12 before a boost with rAd5 vectors expressing Gag and Env four weeks after the second DNA
immunization. Splenocytes were harvested at week 6 and week 10, incubated ex vivo for 5 h with Gag pooled peptides or the dominant peptides DD13/AL11 (A/C) or Env
pool  peptides (B/D), anti-CD28 and brefeldin A before being analyzed by ﬂow cytometry for combined production of IFN, IL-2 and TNF. The frequency of multifunctional
cytokine secreting Gag-speciﬁc (E) or Env-speciﬁc (F) CD4+ T cells (%) at week 10 producing IFN, IL-2 and TNF in any combination are shown, bars represent the median,
n = 4 and data are representative of 2 experiments. *p < 0.05, signiﬁcantly different from animals immunized by EP or #p < 0.05, signiﬁcantly different from animals immunized
by  EP + pIL-12 low.
4754 R.W. Lindsay et al. / Vaccine 31 (2013) 4749– 4758
Fig. 4. Frequency of memory Gag and Env-speciﬁc CD4+ (A) or CD8+ (C) T cells secreting IFN, IL-2 and TNF or the quality of the memory CD4+ Gag-speciﬁc T cell response
(B). Mice were immunized twice, 4 weeks apart with SIV Gag and Env DNA (30 g) by IM or EP +/− pIL-12 (0.3 g) before a boost with rAd5 vectors expressing Gag and
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edian, n = 4 and data are representative of 2 experiments. *p < 0.05, signiﬁcantly d
.5. Electroporation of SIVmac239 Env DNA with high dose
IL-12  inhibits SIV-speciﬁc IgG responses
At week 6, 2 weeks following the second DNA immunization,
he level of SIVmac239-Env speciﬁc IgG quantiﬁed by ELISA was
igniﬁcantly greater in EP and EP + low dose pIL-12 immunized
nimals as compared to EP+ high dose pIL-12 and all other
roups (Fig. 6A). In addition, the median endpoint titers of ani-
als vaccinated by EP +/− pIL-12 were approximately 2 logs
igher than those immunized by IM +/− pIL-12 which wereeptides, the dominant DD13/AL11 peptides or Env pooled peptides, anti-CD28 and
nd TNF (A/C) or IFN, IL-2 and TNF in any combination (B), bars represent the
t from animals immunized by IM.
similar  in level to the response of control PBS immunized ani-
mals. At week 10, 2 weeks following the rAd5 boost, the level
of SIVmac239 Env-speciﬁc IgG was signiﬁcantly greater in the
EP + low dose pIL-12 group, but not the EP only group, as
compared to the EP + high dose pIL-12 group. The median end
point titers of animals vaccinated with EP +/− pIL-12 remained
approximately 1–2 logs higher than those immunized by IM +/−
pIL-12. In addition, SIVmac239 Env-speciﬁc IgG was signiﬁcantly
boosted in the EP + high dose pIL-12 group from week 6 to week
10.
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Fig. 5. Effect of high dose pIL-12 on the frequency (A) and quality (B/C) of memory CD4 and CD8 (D) SIV-speciﬁc cytokine secreting T cells. Mice were immunized twice, 4
weeks  apart with SIV Gag and Env DNA (30 g) by EP with low dose (0.3 g) or high dose (25 g) pIL-12 before a boost with rAd5 vectors expressing Gag and Env. Splenocytes
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eing  analyzed by ﬂow cytometry for total production of IFN, IL-2 and TNF (A/D) 
nd  data are representative of 2 experiments, *p < 0.05, signiﬁcantly different from 
Levels of cross-reactive SIVmac251 (Fig. 6B) and SIVsmE660
nv-speciﬁc IgG (Fig. 6C) showed a similar trend with EP titers being
pproximately 2 logs higher than IM or control animal titers. Addi-
ionally, endpoint titers of EP and EP + low dose pIL-12 immunized
nimals were signiﬁcantly higher than the EP + high dose pIL-12
roup. Following the rAd5 boost, cross reactive SIVmac251 and
IVsmE660 Env-speciﬁc antibodies remained approximately 2 logs
igher in animals immunized by EP +/− low dose pIL-12 than IM
/− low dose pIL-12. Furthermore, cross-reactive IgG remained sig-
iﬁcantly higher in the EP +/− low dose pIL-12 immunized animals
ompared to the EP + high dose pIL-12 group. Finally, we observedant DD13/AL11 peptides or Env pooled peptides, anti-CD28 and brefeldin A before
, IL-2 and TNF in any combination (B/C) with bars representing the median, n = 4
ls immunized by EP.
that  SIVmac251 cross-reactive IgG was  boosted in the EP + low dose
pIL-12, but not the EP only group comparing the titers at week 6
and week 10 (Fig. 6B).
4.  Discussion
The primary objective of this study was to investigate, in the
mouse model, how delivery of the molecular adjuvant pIL-12 alters
the immune responses induced by DNA vaccination. We  chose the
mouse model for the ease and simplicity of analysis while recogniz-
ing that extrapolation to larger animals and humans should be done
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an  mice immunized by IM or EP with SIV Env DNA +/− pIL-12. Serum was collected a
iter, n = 4 and data are representative of 2 experiments. *p < 0.05, signiﬁcantly diffe
eek  6 to week 10.
ith caution. Nevertheless, we believe these studies can be useful
n establishing general principles, help guide optimization of vac-
ine regimens, and suggest experiments that should be conducted
n animal systems where efﬁcacy endpoints can be measured. Our
wn ﬁndings in an NHP SIV challenge study examining a DNA
rime/rAd5 boost regimen suggest a link between the use of pIL-
2 adjuvant in the prime and control of SIV replication [22]. Others
ave also seen effects of IL-12 adjuvant on efﬁcacy [10,19–21]. In
ur previous NHP study, there was a 2 log reduction in peak viral
oad and a 4 log reduction at set point following intrarectal SIV
nfection, which compared favorably to other vaccination strate-
ies [30–32]. While the mechanism of efﬁcacy is currently under
nvestigation, the inclusion of pIL-12 resulted in an enhanced fre-
uency of multifunctional CD4+ T cells. This occurred in the absence
f enhanced antibody responses and may  suggest that vaccine-
nduced SIV-speciﬁc CD4+ T cells may  be advantageous in immune
ontrol of virus replication.
Both  our NHP study and the murine studies reported here have
emonstrated the T cell adjuvant effect of pIL-12 resulted in an
ncreased frequency of multifunctional CD4+ T cells following a
NA prime and maintenance of these as memory cells following
 rAd5 boost. In addition, when the quality of the Gag- and Env-
peciﬁc CD4+ T cell response was examined, it was  observed that
IL-12 had driven differentiation toward a greater frequency of
ells that produce three cytokines (IFN, IL-2 and TNF), as well as
ells that produce both IFN and TNF. Such multifunctional CD4+
-cells have been described to be generated from a more differenti-
ted Th1 T cell and have been shown to play a role in protection afteraccination and endpoint titers calculated by ELISA. Bars represent median endpoint
rom animals immunized by EP + pIL-12 high, #p < 0.05, signiﬁcantly different from
certain viral and parasitic infections [27,33]. A greater frequency
of such multifunctional T cells that can maintain the reservoir of
memory cells and be mobilized quickly as effector cells is a desirable
characteristic of a T cell vaccine [28].
While we observed an enhancement of the frequency and
quality of Gag-speciﬁc CD4+ T cells following both IM and EP
immunization with a low dose of pIL-12 (Fig. 2A), pIL-12 enhanced
Env-speciﬁc CD4+ T cells only in animals immunized by EP (Fig. 2B).
These data suggest that Env CD4+ T cell responses may  require a
higher dose of pIL-12 by IM immunization to see an adjuvant effect
[16,29], and highlight the requirement of a full dose titration of the
adjuvant with both antigens individually and in combination as it
is possible that their requirements for pIL-12 dose are different.
Thus, to establish and enhanced pool of memory CD4 cells speciﬁc
for Gag and Env, a lower dose of pIL-12 is required in combination
with EP.
When a higher dose of pIL-12 was  introduced into the EP arm of
the study, with the intention of enhancing Env-speciﬁc responses, a
negative impact on the frequency of Gag, and to some extent, Env-
speciﬁc CD4+ T cells, was  observed (Fig. 3A and B). IL-12 is known
to stimulate the synthesis of nitric oxide which is required for the
immunostimulatory effects of IL-12; however, high levels of IL-12
can induce apoptosis and immunosuppression when high levels
of nitric oxide and IFN and are induced, which likely explain the
reduced frequency of SIV-speciﬁc CD4+ T cells observed at week 6
[29,34]. Additionally, in the EP + pIL-12 high dose group, pIL-12 was
administered with the Env plasmid in the right leg, while the low
dose of pIL-12 was immunized with the Gag plasmid in the left leg.
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owever, high dose pIL-12 signiﬁcantly reduced the Gag response
–4-fold demonstrating a systemic effect of IL-12 (Fig. 3A). Never-
heless, the immunosuppressive effect of IL-12 did not prevent both
ag and Env-speciﬁc CD4+ T cells from being boosted by rAd5.
Examining  the quality of the boosted CD4+ T cell response, it
as apparent that epitopes represented by Env pool 1 were pref-
rentially boosted by low dose pIL-12 but suppressed by the high
ose, while epitopes in pool 2 showed a trend (3 out of 4 animals)
oward also being enhanced by high dose pIL-12. This discrep-
ncy perhaps reﬂects an enhanced breadth of response induced
y the high dose IL-12 toward epitopes in pool 2 but without fur-
her epitope mapping this difference could simply be attributed to
n enhanced magnitude of response. Notably, the high dose pIL-
2 expanded population of Env pool 2 speciﬁc CD4+ T cells was
ot maintained (Fig. 5C), unlike Gag-speciﬁc responses (Fig. 5B),
uggesting an exhaustion and potential death of these cells as a
esult of extended or excessive IL-12 stimulation and differen-
iation [28]. Once more, this highlights the potential beneﬁts of
onducting a pIL-12 dose titration with speciﬁc antigens individ-
ally and in combination to fully appreciate the effect of IL-12 on
ultiple antigens.
In  addition to the inhibitory effect of pIL-12 on Th1 CD4+ T cells
fter DNA immunization, low dose pIL-12 inhibited the frequency
f SIV-speciﬁc CD8+ T cells (Fig. 3C and D). Furthermore, Env-
peciﬁc CD8+ T cells were inhibited by low dose pIL-12, and further
uppressed by the high dose (Fig. 3D). This additional immuno-
uppressive effect could simply be a result of increased levels of
itric oxide and IFN, but it is possible that under both dose regi-
ens, as a result of extended exposure to an inﬂammatory signal,
D8+ T cells could be driven to further differentiate into short-lived
ffector cells [35,36]. Of note, pIL-12 at either dose did not prevent
he surviving CD8+ T cells from expanding upon a rAd5 boost, or
rom their maintenance through the end of the study. This may  be
n indication of the value of a heterologous prime-boost regimen
or CD8+ memory T cell maintenance when pIL-12 is used during
he prime. Both our NHP and murine study described here did not
ontain animals vaccinated only with DNA which could address
he question of whether pIL-12 is detrimental in a homologous
rime/boost setting for the maintenance of memory CD8+ T cells,
hich have been shown to have a potential role in protection from
IV infection [37–39].
Our  previous NHP study contained all 9 SIVmac239 genes,
hich may  be advantageous in eliciting broad T cell responses,
hich have been linked to protection in an SIV challenge model
nd are potentially important in the mechanism of control of viral
oad. Furthermore, in the vaccinated macaques, no difference was
bserved in the level of SIVmac239 Env-speciﬁc antibodies that
as attributed to pIL-12. Nevertheless, we cannot rule out the
ossibility that SIV replication may  have been suppressed after
nfection by antibodies that directly neutralized virus or induced
ell-mediated mechanisms as described in HIV-1 infection [40,41].
hile EP immunization alone is enough to enhance the gener-
tion of the antibody response compared to IM immunization
s observed in the current murine study (Fig. 6) and by other
nvestigators [10–13], an accumulative adjuvant effect of EP and
ow dose pIL-12 on antibody production was not observed here.
e did however note that the EP + low dose pIL-12 group showed
igniﬁcantly higher SIVmac239-speciﬁc IgG titers compared to the
igh dose group while the EP alone group did not. In addition, the
P + low dose pIL-12 showed a signiﬁcant increase in SIVmac251
ross-reactive IgG following the rAd5 boost while the EP alone
roup did not. This could be explained by a slightly higher titer of
IVmac239 antibodies but may  also hint at an increase in breadth.
 recent NHP study has demonstrated that pIL-12 may  increase
he breadth of the antibody response following SIVmac239 Env
NA immunization by EP 4 times. Signiﬁcantly higher titers of IgG31 (2013) 4749– 4758 4757
recognizing SIVmac251 were detected when pIL-12 was  included
in the vaccine regimen [42]. We  did not observe this IL-12 induced
effect, however there are several differences between the studies
notably the animal species and DNA-only regimen. Nevertheless,
we report signiﬁcant levels of cross-reactive Env-speciﬁc IgG
generated by EP immunization. The role and dose of pIL-12 on the
antibody response in this model is currently under investigation
as several studies have reported an adjuvant effect of protein IL-12
installed by the intranasal route on the enhancement of protective
mucosal and systemic antibody responses [43–45]. Research on
the role of IL-12 on B cell differentiation and development may
additionally explain the immunosuppressive effect of high dose
pIL-12 on systemic antibody responses observed in this study. A
recent study reports that while IL-12 has an established role in
B cell differentiation and function, IL-12 produced from DCs can
inhibit B cell differentiation to germinal center cells and promote
differentiation into short-lived plasmablasts [46].
In  summary, here we show that mice, like NHPs, generated a
multifunctional Th1 T cell phenotype as a result of the molecular
adjuvant pIL-12. Additionally, this study demonstrates a clear dif-
ference between the cellular and humoral immune responses seen
when using high and low dose pIL-12 during a DNA prime and this
may  have important implications for the use of IL-12 as an adjuvant
in animal studies and clinical trials. The level of IL-12 present at the
site of vaccination can be a function of the amount plasmid used, the
use of electroporation (or other method for increasing expression),
and/or the strength of the promoter driving the IL-12 gene. As a
consequence, we believe that the present study suggests that dose
response testing of antigens alone and in combination will be nec-
essary to optimize immune responses and potentially the efﬁcacy of
a  vaccine. Immunization with a high or inhibitory dose of a molecu-
lar adjuvant like pIL-12 however, may  not be feasible in pre-clinical
or clinical trials due to limiting concentrations of DNA  or study
costs. Additionally, these data bring attention to the effect that
route, method of immunization, or the requirement of individual
antigens for differing adjuvant dose within a multi-antigenic vac-
cine can have on both the humoral and cellular immune responses.
If an HIV vaccine inducing a balanced cellular and humoral immune
response is required for efﬁcacy, one must take care to accurately
study the adjuvant effect on each vaccine immunogen, so as to not
bias the immune response in favor of a single antigen or a cellular
over humoral immune response.
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